We report the results of an open trial of botulinum toxin (Botox) in the treatment of 51 @entity1 with disabling @entity400 , classified as dystonic (14), essential (12), combination of dystonic and essential (22), @entity191 (1), peripherally induced (1), and midbrain (1). The average age of the @entity1 was 55.8 years, and duration of symptoms was 13.9 years. During a total of 160 treatment visits, an average of 242 +/- 75 units of Botox was injected per visit in cervical muscles of 42 @entity1 with head @entity400 and 95 +/- 38 in forearm muscles of 10 @entity1 with hand @entity400 ; one @entity1 was injected in both. The average peak effect for all @entity1 was rated as 3.0 (0 to 4 scale). Thirty-five (67%) @entity1 improved (peak effect greater than or equal to 1). The average latency from injection to response was 6.8 days, and the average duration of maximum improvement was 10.5 weeks. Local complications, lasting an average of 20.6 days, were noted in 17 (40%) @entity1 injected for head @entity400 , consisting chiefly of @entity1282 in 12 (29%), transient @entity425 in four (10%), and @entity158 in two (5%). Six (60%) @entity1 with hand @entity400 had transient focal @entity425 . EMG recordings showed decreased amplitude of EMG bursts after Botox treatment. The results of this pilot study indicate that Botox injections can be used to control @entity400 in @entity1 in whom other forms of therapy have failed.

Botulinum toxin treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity425 :: ('MESH:D018908', 'Disease') :: ['weakness', 'neck weakness'] @entity191 :: ('MESH:D010300', 'Disease') :: ['parkinsonian'] @entity400 :: ('MESH:D014202', 'Disease') :: ['tremor', 'tremors'] @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia'] @entity158 :: ('MESH:D010146', 'Disease') :: ['local pain']
@entity400 :: (MESH:D014202,Disease) :: ['tremors']
